Table 3.
Genomic Polymorphisms and Tumor Response in Patients with Rectal Cancer Treated with Neoadjuvant Chemoradiation
| Polymorphism | N‡ | pCR
|
Dworak Response
|
||||
|---|---|---|---|---|---|---|---|
| Yes | No | 1 | 2 | 3 | 4 | ||
| IL-8 T-251A | |||||||
| TT | 38 | 8 (22%) | 28 | 7 | 12 | 9 | 8 |
| TA | 62 | 7 (12%) | 53 | 9 | 29 | 15 | 7 |
| AA | 26 | 4 (16%) | 21 | 4 | 12 | 5 | 4 |
| P value* | 0.37 (0.74) | 0.54 (0.70) | |||||
| MTHFR C677T | |||||||
| CC | 59 | 12 (20%) | 47 | 9 | 23 | 15 | 12 |
| CT | 56 | 4 (8%) | 48 | 9 | 27 | 12 | 4 |
| TT | 11 | 3 (30%) | 7 | 2 | 3 | 2 | 3 |
| P value* | 0.070 (0.37) | 0.50 (0.70) | |||||
| MTHFR A-1298C | |||||||
| AA | 54 | 8 (16%) | 43 | 7 | 26 | 10 | 8 |
| CA | 62 | 8 (13%) | 52 | 12 | 25 | 15 | 8 |
| CC | 8 | 3 (38%) | 5 | 0 | 2 | 3 | 3 |
| P value* | 0.18 (0.72) | 0.30 (0.70) | |||||
| FCGR2A H131R | |||||||
| HH | 35 | 4 (12%) | 30 | 6 | 13 | 11 | 4 |
| HR | 69 | 11 (17%) | 55 | 11 | 31 | 13 | 11 |
| RR | 19 | 4 (22%) | 14 | 2 | 9 | 3 | 4 |
| P value* | 0.61 (0.85) | 0.77 (0.82) | |||||
| FCGR3A V158F | |||||||
| VV | 49 | 6 (12%) | 43 | 7 | 23 | 13 | 6 |
| VF | 37 | 3 (9%) | 32 | 8 | 15 | 9 | 3 |
| FF | 15 | 3 (20%) | 12 | 3 | 8 | 1 | 3 |
| P value* | 0.49 (0.85) | 0.55 (0.70) | |||||
| CYCLIND1 A870G | |||||||
| AA | 32 | 5 (17%) | 25 | 6 | 15 | 4 | 5 |
| AG | 58 | 7 (12%) | 49 | 9 | 23 | 17 | 7 |
| GG | 34 | 6 (18%) | 27 | 5 | 15 | 7 | 6 |
| P value* | 0.76 (0.85) | 0.55 (0.70) | |||||
| XRCC3 Thr241Met | |||||||
| TT | 51 | 6 (12%) | 42 | 11 | 21 | 10 | 6 |
| CT | 55 | 9 (17%) | 45 | 7 | 26 | 12 | 9 |
| CC | 12 | 2 (18%) | 9 | 0 | 4 | 5 | 2 |
| P value* | 0.74 (0.85) | 0.059 (0.24) | |||||
| VEGF C936T | |||||||
| CC | 93 | 13 (15%) | 75 | 16 | 40 | 19 | 13 |
| CT† | 30 | 6 (19%) | 26 | 4 | 13 | 9 | 6 |
| TT† | 2 | ||||||
| P value* | 0.58 (0.85) | 0.33 (0.70) | |||||
| EGFR G497A | |||||||
| GG | 71 | 10 (15%) | 57 | 13 | 24 | 20 | 10 |
| AG | 42 | 8 (19%) | 34 | 5 | 23 | 6 | 8 |
| AA | 12 | 1 (9%) | 10 | 2 | 6 | 2 | 1 |
| P value* | 0.75 (0.85) | 0.61 (0.70) | |||||
| EGFR (CA)n repeat | |||||||
| Both <20 | 58 | 10 (18%) | 47 | 9 | 23 | 15 | 10 |
| Any ≥20 | 47 | 9 (21%) | 34 | 5 | 20 | 9 | 9 |
| P value* | 0.80 (0.85) | 0.83 (0.83) | |||||
| EGF A61G | |||||||
| AA | 54 | 1 (2%) | 49 | 14 | 24 | 11 | 1 |
| AG | 53 | 11 (21%) | 41 | 4 | 25 | 12 | 11 |
| GG | 11 | 5 (45%) | 6 | 2 | 1 | 3 | 5 |
| P value* | <0.001 (0.002) | <0.001 (<0.001) | |||||
| TS 3′ UTR | |||||||
| +/+ | 55 | 8 (15%) | 44 | 7 | 21 | 16 | 8 |
| +/− | 56 | 9 (16%) | 46 | 10 | 25 | 11 | 9 |
| −/− | 14 | 2 (15%) | 11 | 3 | 7 | 1 | 2 |
| P value* | 1.00 (1.00) | 0.24 (0.70) | |||||
| TS 5′ UTR | |||||||
| 2R/2R | 15 | 5 (36%) | 9 | 3 | 1 | 5 | 5 |
| 2R/3R | 56 | 9 (16%) | 46 | 11 | 23 | 12 | 9 |
| 3R/3R | 24 | 0 (0%) | 23 | 4 | 14 | 5 | 0 |
| P value* | 0.006 (0.045) | 0.015 (0.12) | |||||
| COX-2 G-765C | |||||||
| GG | 84 | 15 (19%) | 66 | 12 | 37 | 17 | 15 |
| GC† | 38 | 4 (10%) | 35 | 8 | 16 | 11 | 4 |
| CC† | 3 | ||||||
| P value* | 0.30 (0.72) | 0.47 (0.70) | |||||
| RAD G51C | |||||||
| GG | 102 | 14 (14%) | 84 | 16 | 43 | 25 | 14 |
| GC | 21 | 5 (25%) | 15 | 3 | 9 | 3 | 5 |
| P value* | 0.31 (0.72) | 0.61 (0.70) | |||||
| KRAS let-7 lcs6 poly | |||||||
| TT | 109 | 15 (14%) | 92 | 20 | 48 | 24 | 15 |
| TG† | 14 | 4 (29%) | 10 | 0 | 5 | 5 | 4 |
| GG† | 3 | ||||||
| P value* | 0.23 (0.72) | 0.024 (0.13) | |||||
*
Nominal P values werebased on Fisher’s exact test for pCR and exact conditional test for Dworak response. FDR-adjusted P values were shown in parentheses.
†
Combined in the analysis
‡
Number of patients by each genotype. Some of the patients had response not evaluable.